S&P 500
(0.34%) 5 117.45 points
Dow Jones
(0.31%) 38 358 points
Nasdaq
(0.33%) 15 980 points
Oil
(-0.85%) $83.14
Gas
(2.96%) $1.980
Gold
(-0.03%) $2 346.60
Silver
(-0.10%) $27.51
Platinum
(3.10%) $950.65
USD/EUR
(-0.05%) $0.934
USD/NOK
(0.00%) $11.02
USD/GBP
(-0.30%) $0.798
USD/RUB
(1.84%) $93.57

リアルタイムの更新: Eli Lilly and Co [LLY.DE]

取引所: XETRA セクター: Pharmaceuticals 産業: Drug Manufacturers—General
Upcoming Earnings Alert

Quarter results today
(bmo 2024-04-29)

Expected move: +/- 0.00%

最終更新日時29 4月 2024 @ 23:09

-0.09% 688.30

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 23:09):

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...

Stats
本日の出来高 2 452.00
平均出来高 6 508.00
時価総額 654.41B
EPS €0 ( 2024-02-06 )
Last Dividend €1.130 ( 2023-08-14 )
Next Dividend €0 ( N/A )
P/E 128.18
ATR14 €0.608 (0.09%)

ボリューム 相関

長: -0.06 (neutral)
短: -0.12 (neutral)
Signal:(50.472) Neutral

Eli Lilly and Co 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Eli Lilly and Co 相関 - 通貨/商品

The country flag 0.50
( neutral )
The country flag 0.38
( neutral )
The country flag -0.32
( neutral )
The country flag 0.10
( neutral )
The country flag 0.43
( neutral )
The country flag -0.16
( neutral )

Eli Lilly and Co 財務諸表

Annual 2023
収益: €34.12B
総利益: €27.04B (79.25 %)
EPS: €5.82
FY 2023
収益: €34.12B
総利益: €27.04B (79.25 %)
EPS: €5.82
FY 2022
収益: €28.54B
総利益: €21.91B (76.77 %)
EPS: €6.93
FY 2021
収益: €28.32B
総利益: €21.01B (74.18 %)
EPS: €5.83

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.980
(N/A)
€0.980
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Eli Lilly and Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 5.72 - average (57.84%) | Divividend Growth Potential Score: 6.05 - Stable (21.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.490 2009-05-13
Last Dividend €1.130 2023-08-14
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 41 --
Total Paid Out €27.35 --
Avg. Dividend % Per Year 0.00% --
Score 3.68 --
Div. Sustainability Score 5.72
Div.Growth Potential Score 6.05
Div. Directional Score 5.89 --
Next Divdend (Est)
(2024-09-05)
€1.166 Estimate 20.00 %
Dividend Stability
0.53 Average
Dividend Score
3.68
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PBB.DE Ex Dividend Junior 2023-05-26 Annually 0 0.00%
APC.F Ex Dividend Knight 2023-08-11 Quarterly 0 0.00%
HHFA.DE Ex Dividend Junior 2023-06-16 Annually 0 0.00%
SAP.DE Ex Dividend Knight 2023-05-12 Annually 0 0.00%
CBHD.DE Ex Dividend Knight 2023-05-15 Semi-Annually 0 0.00%
KHNZ.DE Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%
TNE5.DE Ex Dividend Junior 2023-12-12 Semi-Annually 0 0.00%
DR0.DE Ex Dividend Junior 2023-06-30 Sporadic 0 0.00%
MUB.DE Ex Dividend Junior 2023-08-11 Annually 0 0.00%
7BP.F Ex Dividend Knight 2023-09-06 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1541.5006.9310.00[0 - 0.5]
returnOnAssetsTTM0.08191.2007.278.73[0 - 0.3]
returnOnEquityTTM0.4741.5005.858.77[0.1 - 1]
payoutRatioTTM0.777-1.0002.23-2.23[0 - 1]
currentRatioTTM0.9430.800-0.287-0.230[1 - 3]
quickRatioTTM0.5230.800-1.632-1.305[0.8 - 2.5]
cashRatioTTM0.1031.500-0.537-0.806[0.2 - 2]
debtRatioTTM0.394-1.5003.43-5.15[0 - 0.6]
interestCoverageTTM15.001.0005.565.56[3 - 30]
operatingCashFlowPerShareTTM4.472.008.5110.00[0 - 30]
freeCashFlowPerShareTTM-3.322.00-1.660-3.32[0 - 20]
debtEquityRatioTTM2.34-1.5000.633-0.949[0 - 2.5]
grossProfitMarginTTM0.7921.0000.1260.126[0.2 - 0.8]
operatingProfitMarginTTM0.2141.0007.737.73[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1681.000-0.177-0.177[0.2 - 2]
assetTurnoverTTM0.5330.8009.787.82[0.5 - 2]
Total Score5.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM133.881.00010.000[1 - 100]
returnOnEquityTTM0.4742.507.338.77[0.1 - 1.5]
freeCashFlowPerShareTTM-3.322.00-1.107-3.32[0 - 30]
dividendYielPercentageTTM0.6351.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.472.008.5110.00[0 - 30]
payoutRatioTTM0.7771.5002.23-2.23[0 - 1]
pegRatioTTM7.681.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1241.0009.390[0.1 - 0.5]
Total Score6.05

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。